n-Lorem 2025 Nano-rare Patient Colloquium Poster Session
Wei Zhang, Ph.D., MPA Associate Director of Core Research
Mutations in U-rich RNAs are increasingly recognized as drivers of NDDs. Although their short length and structured nature presents challenges, ASO technology offers a unique therapeutic opportunity. This work focuses on a recently identified mutation in RNU4-2, highlighting its functional characterization and n-Lorem’s therapeutic strategy to address toxic effects.
Sizzle reel by Dr. John Rinn, a world-leading expert in long noncoding RNAs
We’re launching Blue4ReNU! Doing something with the color blue, donate & post a video asking others to do the same!
“I’m going #Blue4ReNU in support of (name/those with ReNU Syndrome).
Tagging [4 people]! Show your blue in the next 24 hours!
Donate any combination of 4s & 2s to support the RNU4-2/ReNU Crew!
Add the hashtags and the donation link below. Thank you!”
#blue4renu #renusyndrome #renusyndromeunited #renuhope #donateandnominate
Nicola Whiffin presents "Interpreting variation in small nuclear RNAs in neurodevelopmental disorders" at the 2025 Mutational Scanning Symposium
🚀 New Episode Alert – RareMind: Podcast on Genomics & AI
🎙️ Episode 3 is live now: ReNU Syndrome – RNU4-2 Mutations and Neurodevelopmental Disorders
🧬 In this episode, we explore how RNU4-2, a non-coding RNA gene integral to the major spliceosome, has been identified as the cause of ReNU Syndrome, a newly recognized neurodevelopmental disorder.
🧠 Recent studies uncovered rare de novo variants clustered in an 18-base pair region of RNU4-2, associated with a consistent clinical phenotype: intellectual disability, microcephaly, short stature, and motor delay. These variants disrupt splicing fidelity and highlight the role of non-coding RNAs in the pathogenesis of rare disease.
🔬 This episode reveals how the search beyond protein-coding regions is reshaping our understanding of spliceosomal disorders and driving forward rare disease diagnostics.
🎧 Tune in now and be part of the growing movement transforming RNA biology into clinical insight.
#Genomics #RareDisease #RNA #Neurodevelopment #Spliceosome #ReNU #NonCodingRNA #Podcast #RareMind
Recorded at St Anne's College, University of Oxford on 29th April 2025.
This event brought together key people involved in the discovery of ReNU syndrome, a condition affecting development and learning which was first identified last year yet potentially impacts tens of thousands of families across the world.
Hearing from experts involved in the discovery, this event reflected on the importance of genomic diagnosis for rare conditions and the factors necessary both to identify new conditions, and to learn about what they might mean for patients and families.
The focus of the evening was around the discovery process and the broader implications of receiving a genetic diagnosis, rather than specific practical implications of a ReNU syndrome diagnosis. Where speakers give permission, talks will be available on our website shortly after the event.
Now that we have a diagnosis, what’s next? One of the most critical steps is to gather data to learn more about ReNU syndrome, so that we can apply these learnings towards treatment options. We’re using the Rare-X Data Collection Program to power the research forward.
Standardized genome sequencing and phenotyping of large patient cohorts provide an opportunity for discovering the unknown etiologies. Here we demonstrate our computational approach to rare disease association analysis on the 100,000 Genomes Project dataset, comprising building a compact database, the "Rareservoir", containing rare variant genotypes and phenotypes, and applying our rare disease association method "BeviMed"…
